Jacqueline James
Overview
Explore the profile of Jacqueline James including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
531
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Berggren K, Cruz S, Hixon M, Cowan A, Keysar S, Craig S, et al.
Oncogene
. 2019 Aug;
38(48):7329-7341.
PMID: 31417185
Radiation therapy (RT) is a cornerstone of treatment in the management of head and neck squamous cell carcinomas (HNSCC), yet treatment failure and disease recurrence are common. The p38/MK2 pathway...
12.
Humphries M, Hynes S, Bingham V, Cougot D, James J, Patel-Socha F, et al.
J Oncol
. 2019 Jan;
2018:2937012.
PMID: 30651729
The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, there is a lack of consensus on how to deliver PD-L1 as a...
13.
McMenamin U, Trainor J, Coleman H, McManus D, McQuaid S, Bingham V, et al.
Oncotarget
. 2018 Nov;
9(82):35300-35312.
PMID: 30450159
Introduction: A striking epidemiological feature of esophageal adenocarcinoma (EAC) is its strong, unexplained male predominance but few studies have evaluated the prevalence of sex hormone receptor expression in EAC. Results:...
14.
Spence A, Trainor J, McMenamin U, Turkington R, McQuaid S, Bingham V, et al.
Histopathology
. 2018 Nov;
74(4):587-596.
PMID: 30408225
Aims: High prostaglandin endoperoxide synthase-2 (PTGS2) enzyme expression in oesophageal adenocarcinoma has been shown to independently predict poor prognosis; however, the evidence is inconsistent. The aim of this study was...
15.
Robinson M, James J, Thomas G, West N, Jones L, Lee J, et al.
J Pathol Clin Res
. 2018 Nov;
5(2):91-99.
PMID: 30407751
While pathologists have always played a pivotal role in clinical trials ensuring accurate diagnosis and staging, pathology data from prognostic and predictive tests are increasingly being used to enrol, stratify...
16.
Humphries M, McQuaid S, Craig S, Bingham V, Maxwell P, Maurya M, et al.
J Thorac Oncol
. 2018 Oct;
14(1):45-53.
PMID: 30296485
Introduction: Patient suitability to anti-programmed death ligand 1 (PD-L1) immune checkpoint inhibition is key to the treatment of NSCLC. We present, applied to PD-L1 testing: a comprehensive cross-validation of two...
17.
Blayney J, Cairns L, Li G, McCabe N, Stevenson L, Peters C, et al.
Oncotarget
. 2018 May;
9(26):18518-18528.
PMID: 29719622
Background: The current TNM staging system for oesophageal adenocarcinoma (OAC) has limited ability to stratify patients and inform clinical management following neo-adjuvant chemotherapy and surgery. Results: Functional genomic analysis of...
18.
Maxwell P, Hynes S, Fuchs M, Craig S, McGready C, Mclean F, et al.
J Clin Pathol
. 2018 Feb;
72(3):225-231.
PMID: 29386326
Aims: Although there have been excellent reports in the literature of validating next-generation sequencing, comparisons between two systems are not often published due to cost and time. We set out...
19.
Bingham V, McIlreavey L, Greene C, ODoherty E, Clarke R, Craig S, et al.
Oncotarget
. 2017 Dec;
8(55):93392-93403.
PMID: 29212158
Immunohistochemistry remains the overwhelming technique of choice for test biomarker evaluation in both clinical or research settings when using formalin-fixed, paraffin embedded tissue sections. However, validations can be complex with...
20.
Hitchen S, James J, Thachil J
Eur J Intern Med
. 2016 Jan;
32:e26-7.
PMID: 26796873
No abstract available.